McLean G - Search Results

1

The Impact of Evolving SARS-CoV-2 Mutations and Variants on COVID-19 Vaccines.

McLean G, Kamil J, Lee B, Moore P, Schulz TF, Muik A, Sahin U, Türeci Ö, Pather S. McLean G, et al. mBio. 2022 Apr 26;13(2):e0297921. doi: 10.1128/mbio.02979-21. Epub 2022 Mar 30. mBio. 2022. PMID: 35352979 Free PMC article. Review.

2

Cross-serotype immunity induced by immunization with a conserved rhinovirus capsid protein.

Glanville N, McLean GR, Guy B, Lecouturier V, Berry C, Girerd Y, Gregoire C, Walton RP, Pearson RM, Kebadze T, Burdin N, Bartlett NW, Almond JW, Johnston SL. Glanville N, et al. PLoS Pathog. 2013;9(9):e1003669. doi: 10.1371/journal.ppat.1003669. Epub 2013 Sep 26. PLoS Pathog. 2013. PMID: 24086140 Free PMC article.

3

The potential for a protective vaccine for rhinovirus infections.

Williams GR, Kubajewska I, Glanville N, Johnston SL, Mclean GR. Williams GR, et al. Expert Rev Vaccines. 2016 May;15(5):569-71. doi: 10.1586/14760584.2016.1142375. Epub 2016 Feb 15. Expert Rev Vaccines. 2016. PMID: 26766290 Free article. No abstract available.

4

Vaccine strategies to induce broadly protective immunity to rhinoviruses.

McLean GR. McLean GR. Hum Vaccin Immunother. 2020 Mar 3;16(3):684-686. doi: 10.1080/21645515.2019.1661207. Epub 2019 Sep 20. Hum Vaccin Immunother. 2020. PMID: 31464554 Free PMC article.

5

IgA binds to the AD-2 epitope of glycoprotein B and neutralizes human cytomegalovirus.

Siddiqui S, Hackl S, Ghoddusi H, McIntosh MR, Gomes AC, Ho J, Reeves MB, McLean GR. Siddiqui S, et al. Immunology. 2021 Mar;162(3):314-327. doi: 10.1111/imm.13286. Epub 2020 Dec 13. Immunology. 2021. PMID: 33283275 Free PMC article.

6

Decoding Covid-19 with the SARS-CoV-2 Genome.

Ellis P, Somogyvári F, Virok DP, Noseda M, McLean GR. Ellis P, et al. Curr Genet Med Rep. 2021;9(1):1-12. doi: 10.1007/s40142-020-00197-5. Epub 2021 Jan 9. Curr Genet Med Rep. 2021. PMID: 33457109 Free PMC article. Review.

7

Rhinovirus infections and immunisation induce cross-serotype reactive antibodies to VP1.

McLean GR, Walton RP, Shetty S, Peel TJ, Paktiawal N, Kebadze T, Gogsadze L, Niespodziana K, Valenta R, Bartlett NW, Johnston SL. McLean GR, et al. Antiviral Res. 2012 Sep;95(3):193-201. doi: 10.1016/j.antiviral.2012.06.006. Epub 2012 Jun 26. Antiviral Res. 2012. PMID: 22742898

8

The application of prophylactic antibodies for rhinovirus infections.

Privolizzi R, Solari R, Johnston SL, McLean GR. Privolizzi R, et al. Antivir Chem Chemother. 2014 Apr 11;23(5):173-7. doi: 10.3851/IMP2578. Antivir Chem Chemother. 2014. PMID: 23598287 Free article. Review.

9

Epitope-Specific Humoral Responses to Human Cytomegalovirus Glycoprotein-B Vaccine With MF59: Anti-AD2 Levels Correlate With Protection From Viremia.

Baraniak I, Kropff B, McLean GR, Pichon S, Piras-Douce F, Milne RSB, Smith C, Mach M, Griffiths PD, Reeves MB. Baraniak I, et al. J Infect Dis. 2018 May 25;217(12):1907-1917. doi: 10.1093/infdis/jiy102. J Infect Dis. 2018. PMID: 29528415 Free PMC article.

10

Protection from cytomegalovirus viremia following glycoprotein B vaccination is not dependent on neutralizing antibodies.

Baraniak I, Kropff B, Ambrose L, McIntosh M, McLean GR, Pichon S, Atkinson C, Milne RSB, Mach M, Griffiths PD, Reeves MB. Baraniak I, et al. Proc Natl Acad Sci U S A. 2018 Jun 12;115(24):6273-6278. doi: 10.1073/pnas.1800224115. Epub 2018 Apr 23. Proc Natl Acad Sci U S A. 2018. PMID: 29686064 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

322 results

Search Page